(Q33385748)

26 July 2017

1 reference

title

Benefit-risk assessment of sunitinib in gastrointestinal stromal tumours and renal cancer (English)

1 reference

26 July 2017

Sandrine Faivre

2

0 references

author name string

Nathalie Theou-Anton

series ordinal

1

1 reference

26 July 2017

Chantal Dreyer

series ordinal

3

1 reference

26 July 2017

Eric Raymond

series ordinal

4

1 reference

26 July 2017

publication date

1 January 2009

1 reference

26 July 2017

1 reference

26 July 2017

volume

32

1 reference

26 July 2017

issue

9

1 reference

26 July 2017

page(s)

717-734

1 reference

Rhebbing up mTOR: New Insights on TSC1 and TSC2, and the Pathogenesis of Tuberous Sclerosis

26 July 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00002018-200932090-00003

Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors.

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00002018-200932090-00003

Amlodipine, enalapril, and dependent leg edema in essential hypertension

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00002018-200932090-00003

Targeted therapy for metastatic renal cell carcinoma

21 January 2018

1 reference

12 December 2020

Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer

1 reference

12 December 2020

Mechanisms of hypertension associated with BAY 43-9006.

1 reference

12 December 2020

RET and neuroendocrine tumors

1 reference

12 December 2020

SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model

1 reference

12 December 2020

Electrocardiographic and cardiovascular effects of the 5-hydroxytryptamine3 receptor antagonists

1 reference

12 December 2020

The role of CSF-1 in normal physiology of mammary gland and breast cancer: an update

1 reference

12 December 2020

Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib

1 reference

12 December 2020

Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma

1 reference

12 December 2020

Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor

1 reference

12 December 2020

1 reference

12 December 2020

Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer

1 reference

12 December 2020

Sunitinib (Sutent, SU11248), a small-molecule receptor tyrosine kinase inhibitor, blocks function of the ATP-binding cassette (ABC) transporters P-glycoprotein (ABCB1) and ABCG2.

1 reference

12 December 2020

Molecular basis for sunitinib efficacy and future clinical development

1 reference

12 December 2020

The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation

1 reference

12 December 2020

Kinase inhibition with BAY 43-9006 in renal cell carcinoma

1 reference

12 December 2020

Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib

1 reference

12 December 2020

A multicentre study of the safety and efficacy of amlodipine in mild to moderate hypertension

1 reference

12 December 2020

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

1 reference

12 December 2020

Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma

1 reference

12 December 2020

Biology of gastrointestinal stromal tumors.

1 reference

12 December 2020

Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trial

1 reference

12 December 2020

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

1 reference

12 December 2020

Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma

1 reference

12 December 2020

Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial

1 reference

12 December 2020

Sorafenib in advanced clear-cell renal-cell carcinoma

1 reference

12 December 2020

SCF/c-kit signaling is required for cyclic regeneration of the hair pigmentation unit

1 reference

12 December 2020

Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate

1 reference

12 December 2020

Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor

1 reference

12 December 2020

A population-based study evaluating the impact of sunitinib on overall survival in the treatment of patients with metastatic renal cell cancer

1 reference

12 December 2020

PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib

1 reference

12 December 2020

Sunitinib in patients with metastatic renal cell carcinoma

1 reference

12 December 2020

Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with "standard of care" therapeutic agents for the treatment of breast cancer

1 reference

12 December 2020

Cutaneous side-effects of kinase inhibitors and blocking antibodies

1 reference

12 December 2020

Hand-foot syndrome and seborrheic dermatitis-like rash induced by sunitinib in a patient with advanced renal cell carcinoma

1 reference

12 December 2020

SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer

1 reference

12 December 2020

Novel approaches in the therapy of metastatic renal cell carcinoma.

1 reference

12 December 2020

Hypoxia-inducible factor-1 and oncogenic signalling

1 reference

12 December 2020

Thyrotoxicosis during sunitinib treatment for renal cell carcinoma.

1 reference

12 December 2020

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

1 reference

12 December 2020

Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer

1 reference

12 December 2020

Sunitinib malate for the treatment of solid tumours: a review of current clinical data

1 reference

12 December 2020

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

1 reference

12 December 2020

Angiogenesis inhibitors and hypertension: an emerging issue

1 reference

12 December 2020

New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.

1 reference

12 December 2020

Hypertension as a predictive factor of Sunitinib activity

1 reference

12 December 2020

Heart failure associated with sunitinib malate: a multitargeted receptor tyrosine kinase inhibitor

1 reference

12 December 2020

Immunotherapy in metastatic renal cell carcinoma

1 reference

12 December 2020

Activation of HIF1alpha ubiquitination by a reconstituted von Hippel-Lindau (VHL) tumor suppressor complex

1 reference

12 December 2020

General involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxia

1 reference

12 December 2020

Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib

1 reference

12 December 2020

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

1 reference

12 December 2020

Effect of food on the pharmacokinetics of sunitinib malate (SU11248), a multi-targeted receptor tyrosine kinase inhibitor: results from a phase I study in healthy subjects

1 reference

12 December 2020

Biology of gastrointestinal stromal tumors: KIT mutations and beyond

1 reference

12 December 2020

Effect of treatment with a colloidal oatmeal lotion on the acneform eruption induced by epidermal growth factor receptor and multiple tyrosine-kinase inhibitors

1 reference

12 December 2020

Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma

1 reference

12 December 2020

A comparative review of the adverse effects of calcium antagonists

1 reference

12 December 2020

Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma

1 reference

12 December 2020

In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.

1 reference

12 December 2020

Quantitation of SU1 1248, an oral multi-target tyrosine kinase inhibitor, and its metabolite in monkey tissues by liquid chromatograph with tandem mass spectrometry following semi-automated liquid-liquid extraction

1 reference

12 December 2020

State-of-the art therapy for gastrointestinal stromal tumors

1 reference

12 December 2020

Normal and oncogenic FLT3

1 reference

12 December 2020

Hair depigmentation is a biological readout for pharmacological inhibition of KIT in mice and humans

1 reference

12 December 2020

MAP kinase links the transcription factor Microphthalmia to c-Kit signalling in melanocytes

1 reference

12 December 2020

10.2165/00002018-200932090-00003

Identifiers

DOI

1 reference

Dimensions Publication ID

26 July 2017

1046797294

0 references

1 reference